Top E&L Risk Assessment Mistakes—and How to Avoid Them



Top E&L Risk Assessment Mistakes—and How to Avoid Them

Published on 03/12/2025

Top E&L Risk Assessment Mistakes—and How to Avoid Them

Understanding Extractables and Leachables in Pharmaceutical Packaging

Extractables and leachables (E&L) represent a critical aspect of pharmaceutical packaging compliance and risk management. These contaminants can originate from packaging materials and pose potential risks to product safety and efficacy. In the context of regulatory requirements, it is essential for pharmaceutical companies to fully comprehend the implications associated with E&L.

The FDA and EMA have set forth guidelines mandating comprehensive assessments to ensure that leachables and extractables do not adversely affect drug products. As stated in FDA guidelines, companies must establish robust validation processes to analyze E&L risks adequately.

This article delves into common mistakes made in E&L risk assessment, particularly focusing on the analytical evaluation threshold (AET) and dose-based threshold (DBT) calculations. Furthermore, it emphasizes best practices for container closure integrity (CCI) testing and single-use systems validation.

Common Mistakes in E&L Risk Assessment

E&L assessments can vary qualitatively and quantitatively across different products and packaging systems. An array of mistakes may arise in the evaluation process, leading to potentially severe regulatory repercussions. Here are some prevalent errors:

  • Inadequate Knowledge of AET/DBT: One of the foundational components of any E&L risk assessment is the determination of the analytical evaluation threshold (AET) and dose-based threshold (DBT). Miscalculations or misunderstandings can lead to under or overestimating the risks associated with leachables.
  • Assuming All E&L Risks Are Equivalent: Not all extractables or leachables carry the same risk. Some compounds possess greater toxicity profiles and require thorough evaluation. Failing to differentiate between the levels of risk linked to specific substances can have dire consequences.
  • Neglecting Real-World Conditions: A common mistake in E&L assessments is not simulating real-world usage of drug products. Testing conditions should mirror actual storage and usage scenarios to provide accurate risk profiles for contaminants.
  • Insufficient Sampling: Inadequate sampling can skew results of E&L analysis. A holistic review of the entire packaging assembly and the potential for variances in material composition is critical for obtaining a clear picture.

Conducting a Comprehensive E&L Risk Assessment

To mitigate risks and ensure compliance, it is crucial to perform an in-depth E&L risk assessment. The following steps will guide you through this process:

Step 1: Material Characterization

Begin by performing exhaustive characterization of all materials associated with the packaging system. Document the chemical composition, intended use, and any specific properties of the materials employed. Understanding the potential risk profile of the components is key to informing further evaluations.

This step prepares you for potential E&L issues by identifying materials that are more prone to extractables or leachables. Utilize resources such as USP guidelines and the PQRI guidelines to establish clear eligibility and risk factors for each component.

Step 2: Establishing AET and DBT

The analytical evaluation threshold (AET) is determined as the concentration above which leachables require identification and characterization. The dose-based threshold (DBT), on the other hand, establishes tolerable levels. Calculating these thresholds accurately is essential for compliance and safety.

Engage with cross-functional teams to utilize quantitative toxicology data when establishing AET and DBT values. Furthermore, correlate these values with the specified target product profile (TPP) for the pharmaceutical product.

Step 3: Conducting Extractables Testing

Extractables testing should be performed using appropriate methodologies that simulate the product’s real-life conditions. Utilize conditions consistent with the most extreme scenarios (e.g., elevated temperature, pressure). Common methods for performing these tests include:

  • High-performance liquid chromatography (HPLC)
  • Gas chromatography-mass spectrometry (GC-MS)
  • Liquid chromatography-mass spectrometry (LC-MS)

Documentation of the extraction conditions should be comprehensive enough to allow reproducibility of results. Identify all extractables and correlate them back to their origin in the manufacturing process.

Step 4: Characterizing Leachables in Drug Products

Once extractables testing is completed, the next step is leachables testing on the drug product itself. This involves analyzing the final product for identified extractables, including threshold levels determined earlier. The process includes:

  • Direct infusion of samples into analytical instruments
  • Review of potential leachable compounds against established databases
  • Identifying the most harmful compounds based on historical data

Characterizing leachables ensures that any harmful substances are accurately monitored and controlled throughout the product’s lifecycle.

Step 5: Risk Evaluation and Management

Risk evaluation must be conducted after assessing both extractables and leachables to identify any points of concern. Use qualitative and quantitative analytical data to evaluate risk and consider the safety and efficacy of the drug product when developing mitigation strategies.

Risk management strategies should include ongoing monitoring of container closure integrity (CCI) testing. It is imperative to verify that the chosen packaging system retains optimal performance over time. Consistently reevaluating strategies will enhance the reliability of the product in the market.

Best Practices for E&L Risk Assessment

Implementing best practices in E&L risk assessment is paramount to ensuring compliance and safeguarding product quality:

  • Utilizing Robust Data: Ensure that all data used in AET and DBT calculations are sourced from reputable studies and databases. Cross-reference with available literature, including EU GMP Annex 1 and industry publications.
  • Incorporating a Multi-Disciplinary Approach: Leverage cross-functional teams to establish a comprehensive view of risks associated with both E&L. Include insights from quality assurance, regulatory compliance, manufacturing, and toxicology experts.
  • Regularly Updating Protocols: Regulatory expectations are dynamic; thus, protocols and risk assessment strategies must be reviewed and updated regularly to meet evolving standards.
  • Maintaining Transparency with Regulatory Bodies: Engage directly with regulatory agencies by sharing risk assessment data and methodologies. This proactive approach fosters trust and can streamline future assessments.

Conclusion

In summary, the intricate relationship between extractables and leachables presents a significant challenge to pharmaceutical development. Overcoming common pitfalls in E&L risk assessment necessitates a strategic, thorough approach, aligning practices with regulatory expectations.

By implementing the outlined steps and best practices, pharmaceutical professionals can navigate E&L challenges effectively, safeguarding product integrity and ensuring compliance. Given the importance of E&L in maintaining industry standards, relentless pursuit of knowledge, accuracy, and regulatory alignment will lead to better patient outcomes and product reliability.